

Medical Preferred Drug List (Medicaid) – July 2025

Prepared for CA, IA, ID, NM, NV, SC, UT, and WI

| Drug Class | Non-Preferred Product(s) | Preferred Product(s) |
|--|---|---|
| Alpha-1 Antitrypsin Deficiency | Aralast® (Alpha-1-Proteinase Inhibitor) Glassia® (Alpha-1-Proteinase Inhibitor) Zemaira® (Alpha-1-Proteinase Inhibitor) | Prolastin C® (Alpha-1-Proteinase Inhibitor) |
| Antiviral-MAB-RSV | Synagis® (palivizumab) | Beyfortus® (nirsevimab-alip) |
| Autoimmune – Infliximab/Remicade | Remicade (infliximab) Infliximab (unbranded) Renflexis (infliximab-abda) Zymfentra (infliximab-dyyb) | Avsola (infliximab-axxq) Inflectra (infliximab-dyyb) |
| *Hematologic, Colony Stimulating Factors – Short Acting | Granix® (tbo-filgrastum) Leukine® (sargramostim) Neupogen® (filgrastim) Nivestym® (filgrastim-aafi) | Zarxio® (filgrastim-sndz) |
| *Hematologic, Colony Stimulating Factors – Long Acting | Ziextenzo® (pegfilgrastim-bmez) Udenyca® (pegfilgrastim-cbqv) Nyvepria™ (pegfilgrastim-apgf) Fylnetra (pegfilgrastim-pbbk) Rolvedon (eflapergrastim-xnst) Ryzneuta (efbmalenograstim alfa vuxw) Stimufend (pegfilgrastim-fpgk) | Fulphila™ (pegfilgrastim-jmdb) Neulasta® (pegfilgrastim) |
| Heme, IV Iron | Feraheme (ferumoxytol) Ferumoxytol (generic) Injectafer (ferric carboxymaltose) Monoferric (ferric derisomaltose) | Ferrlecit (sodium ferric gluconate) Infed (Iron dextran) Venofer (iron sucrose) |
| Immune Globulin – IV | Asceniv (immune globulin) Carimune (immune globulin) Gammaplex (immune globulin) Panzyga (immune globulin) Vivaglobin (immune globulin) | Bivigam (immune globulin) Flebogamma (immune globulin) Gammagard (immune globulin) Gammagard S/D (immune globulin) Gamunex-C (immune globulin) Gammaked (immune globulin) Octagam (immune globulin) Privigen (immune globulin) |
| Lysosomal Storage Disorders – Gaucher Disease | VPRIV® (velaglycerase alfa) Elelyso® (taliglucerase alfa) | Cerezyme® (imiglucerase) |
| Multiple Sclerosis (Infused) | Lemtrada® (alemtuzumab) Briumvi (ublituximab-xiyy) Ocrevus Zunovo® (ocrelizumab- hyaluronidase) | Tysabri® (natalizumab) Ocrevus® (ocrelizumab) |

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

| Drug Class | Non-Preferred Product(s) | Preferred Product(s) |
|---|--|--|
| | Tyruko (natalizumab) | |
| Myasthenia Gravis/Paroxysmal Nocturnal Hemoglobinuria (PNH) | Empaveli® (pegcetaclopan) Soliris® (eculizumab) Ultomiris® (Ravulizumab-cwrz) | Bkemv®(eculizumab-aeab) Epysqli®(eculizumab-aagh) |
| Osteoarthritis, Viscosupplements | Gelsyn-3® (sodium hyaluronate) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis (sodium hyaluronate) Orthovisc® (1% sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) SynoJoynt® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) Triluron® (sodium hyaluronate) TriVisc®(sodium hyaluronate) Visco-3® (1% sodium hyaluronate) | Euflexxa® (1% sodium hyaluronate) |
| *Oncology | Alymsys (bevacizumab-maly) **Avastin® (bevacizumab) Vegzelma (bevacizumab-adcd) | Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr) |
| | Herceptin® (trastuzumab) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) Hercessi (trastuzumab-strf) Herzuma® (trastuzumab-pkrb) Ogivri™ (trastuzumab-dkst) Ontruzant® (trastuzumab-dttb) Trazimera™ (trastuzumab-qyyp) | Kanjinti™(trastuzumab-anns) |
| *Rituximab | Rituxan® (rituximab) Rituxan Hycela®(rituximab-hyaluronidase) Riabni™ (rituximab-arrx) Truxima®(rituximab-abbs) | Ruxience®(rituximab-pvvr) |
| Retinal Disorders (Eye) | Eylea®(aflibercept) Pavblu®(aflibercept) Enzeevu®(aflibercept) Ahzantive®(aflibercept) Opviz®(aflibercept) Lucentis®(ranibizumab) Byooviz®(ranibizumab) Cimerli® (ranibizumab-eqrn) Beovu® (brolucizumab-dbl) Macugen (pegaptanib) Susvimo™ (ranibizumab) Vabysmo™ (faricimab-svoa) Visudyne® (verteporfin) | **Avastin® (bevacizumab) |

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

